AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24999104
Drug: Common atropine
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common atropine (CA) gel
Trial: 24999104
Drug: Modified atropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified atropine (MA) gel
Trial: 10442679
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme (ACE) inhibitor as first-line treatment
Trial: 10442679
Drug: Diuretic added
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diuretic added to ACE inhibitor
Trial: 11933550
Drug: Carvedilol (beta-blocker)
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol (beta-blocker)
Trial: 10442679
Drug: ACE inhibitors,
RxNorm normalized name: ACE INHIBITORS, PLAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors, diuretics, beta-blockers (e.g. carvedilol), and digoxin
Trial: 18324601
Drug: Combined programme
RxNorm normalized name: PUMP,LUTREPULSE PROGRAMMABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined programme (intensive psychosocial relapse-prevention + anxiety treatment with cognitive behavioural therapy and optional SSRI)
Trial: 12957248
Drug: RT dose
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RT dose <75 Gy + STAD (Group A)
Trial: 12957248
Drug: RT dose
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RT dose >=75 Gy alone (Group B)
Trial: 10897156
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of lamotrigine (100 mg)
Trial: 10897156
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of lamotrigine (100 mg)
Trial: 1570385
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide administered during acquisition
Trial: 3045295
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg orally)
Trial: 3880523
Drug: Edrophonium (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium (10 mg i.v.)
Trial: 3880523
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg orally) and Edrophonium (10 mg i.v.)
Trial: 6111742
Drug: Analgesic drugs
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic drugs
Trial: 29976193
Drug: Social and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social and Therapeutic Horticulture (STH) intervention with 6 monthly sessions led by horticulturists and a psychotherapist
Trial: 20598993
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg pretreatment before PCI
Trial: 18240191
Drug: Intensive exercise
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive exercise therapy (IET)
Trial: 11245027
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with CP (cisplatin + cyclophosphamide) or CAP (CP + adriamycin) regimen
Trial: 11245027
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (CP, CAP, or CEP, E = VP16)
Trial: 3277481
Drug: Oral atropine
RxNorm normalized name: atropine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral atropine 0.04 mg/kg
Trial: 3277481
Drug: Oral atropine
RxNorm normalized name: atropine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral atropine 0.02 mg/kg
Trial: 2310661
Drug: Intravenous hydralazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydralazine
Trial: 28521880
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose
Trial: 26041653
Drug: Brief behavioural
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief behavioural intervention to promote regular self-weighing, including daily weighing encouragement and support materials such as a weight record card
Trial: 11312429
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied twice daily for 6 weeks
Trial: 11312429
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied once daily for 6 weeks
Trial: 11312429
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied twice daily 3 times/week for 6 weeks
Trial: 11312429
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied once daily 3 times/week for 6 weeks
Trial: 7956718
Drug: Theophylline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (5 mg/kg) in oral solution
Trial: 25173483
Drug: M-001 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-001 (500 mcg, non-adjuvanted or adjuvanted)
Trial: 22850914
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (IT) with weekly visits for medication adjustments and educational plan for six weeks
Trial: 19435491
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (IT)
Trial: 18408560
Drug: Albuterol (short-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (short-acting beta2-agonist)
Trial: 15759530
Drug: Bobath treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bobath treatment
Trial: 1791612
Drug: nisoldipine 5
RxNorm normalized name: nisoldipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nisoldipine 5 mg twice daily
Trial: 1791612
Drug: nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine 10 mg twice daily
Trial: 2684134
Drug: Standard behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard behavioural treatment
Trial: 31452920
Drug: ENHANCED (technology-supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENHANCED (technology-supported treatment with digital scale and Fitbit Zip)
Trial: 31452920
Drug: Standard behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard behavioural treatment and ENHANCED
Trial: 22490950
Drug: 0.5% Loteprednol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% Loteprednol Etabonate ophthalmic suspension
Trial: 12021221
Drug: tirofiban/heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tirofiban/heparin
Trial: 8094768
Drug: heparin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heparin alone
Trial: 10208508
Drug: Model topical
RxNorm normalized name: Model AA 2012 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model topical agent
Trial: 1972611
Drug: Acebutolol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (0.1 mg/kg i.v. bolus over 30 s)
Trial: 1972611
Drug: Esmolol (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (loading dose 500 micrograms/kg over 1 min followed by 100 micrograms/kg per min continuous infusion)
Trial: 418585
Drug: Oral thyrotropin
RxNorm normalized name: Thyrotropin
DrugBank: Thyrotropin (DB15263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral thyrotropin releasing hormone (TRH) 40 mg
Trial: 31765428
Drug: Four-component combination
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-component combination pill (polypill)
Trial: 27640727
Drug: Hypodermoclysis administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypodermoclysis administered by caregivers after a 45-minute training session
Trial: 24794289
Drug: Serious games
RxNorm normalized name: Encora AM Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serious games (SG) as an adjuvant to conventional treatment
Trial: 24794289
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment for CP
Trial: 24843499
Drug: Liraglutide 0.6
RxNorm normalized name: liraglutide 0.6 mg/0.1 mL (18 mg/3 mL) SUBCUT PEN INJECTOR (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 0.6 mg/day
Trial: 18025845
Drug: Periprostatic bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprostatic bupivacaine (0.5% 20 ml) injection (group I)
Trial: 18025845
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline NaCl 0.9% 20 ml injection, group II)
Trial: 1535653
Drug: Korean HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean HBV vaccine
Trial: 1535653
Drug: U.S. HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: U.S. HBV vaccine
Trial: 6532586
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a specific vasopressin antagonist acting at the vascular site
Trial: 9578335
Drug: Psyllium (7.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium (7.4 g)
Trial: 7523130
Drug: Neoadjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant hormonal treatment with GnRH analogue (triptorelin) for 3 months
Trial: 2694858
Drug: Alfentanil combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil combination anaesthesia
Trial: 2694858
Drug: Ethrane inhalation
RxNorm normalized name: Ethrane Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethrane inhalation anaesthesia
Trial: 902677
Drug: Indomethacin alone
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin alone (preparation C)
Trial: 902677
Drug: Indomethacin-antacid combination
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin-antacid combination (preparation A)
Trial: 902677
Drug: Indomethacin-antacid combination
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin-antacid combination (preparation B)
Trial: 25086659
Drug: RIS+OLZ (augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIS+OLZ (augmentation with olanzapine)
Trial: 25086659
Drug: OLZ-RIS (augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLZ-RIS (augmentation with risperidone)
Trial: 19640677
Drug: Individual cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive-behavioral family-based therapy (CBFT)
Trial: 19640677
Drug: Group cognitive-behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavioral family-based therapy (CBFT)
Trial: 14615876
Drug: Psilocybin (PY)
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (PY) - 45 microg/kg (very low dose)
Trial: 14615876
Drug: Psilocybin (PY)
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (PY) - 115 microg/kg (low dose)
Trial: 14615876
Drug: Psilocybin (PY)
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (PY) - 215 microg/kg (medium dose)
Trial: 14615876
Drug: Psilocybin (PY)
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (PY) - 315 microg/kg (high dose)
Trial: 3056751
Drug: Adjuvant hormono-chemotherapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormono-chemotherapy (Tamoxifen for 6 months, and 6-monthly cycles of vincristine, adriamycin, and cyclophosphamide)
Trial: 519956
Drug: Propranolol (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (single oral dose)
Trial: 28136072
Drug: Pazopanib (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (800 mg once daily for up to 24 months)
Trial: 21932561
Drug: Stepwise increase
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepwise increase in the extent of combined salmoterol/fluticason therapy
Trial: 21932561
Drug: Long-term stable-dose
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term stable-dose salmoterol/fluticason therapy
Trial: 21932561
Drug: Salmoterol/fluticason therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmoterol/fluticason therapy with gradual decrease of the dose and/or transition to an alternative variant
Trial: 19825213
Drug: Fermented milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented milk containing Lactobacillus acidophilus 145 and Bifidobacterium longum BB536 (125 g three times a day for 4 weeks)
Trial: 15193791
Drug: Dentine bonding
RxNorm normalized name: dendropanax dentiger root with stem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentine bonding agent (DBA) - Prime & Bond NT applied after acid-etching
Trial: 2003792
Drug: Topical 0.01%
RxNorm normalized name: tretinoin topical 0.01% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.01% dexamethasone sodium phosphate drops
Trial: 22950711
Drug: Nimodipine (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (90 mg/d)
Trial: 8487598
Drug: Nicardipine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (60 mg/d)
Trial: 4037255
Drug: Histamine dihydrochloride
RxNorm normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine dihydrochloride 1 mg/ml
Trial: 4037255
Drug: Histamine dihydrochloride
RxNorm normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine dihydrochloride 5 mg/ml
Trial: 4037255
Drug: Histamine dihydrochloride
RxNorm normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine dihydrochloride 10 mg/ml
Trial: 26839144
Drug: Abituzumab 750
RxNorm normalized name: sacituzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abituzumab 750 mg
Trial: 26839144
Drug: Abituzumab 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abituzumab 1,500 mg
Trial: 25280410
Drug: Fructose supplementation
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose supplementation (120 g/d for 3 days)
Trial: 16295154
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus 3 hours contact with a pediatric nurse practitioner (PNP) for counseling, instruction, and assistance with implementation of the recommended treatment plan
Trial: 16295154
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (1-hour consultation session and written treatment plan)
Trial: 28395131
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (220 mg zinc sulfate containing 50 mg elemental zinc daily for 12 weeks)
Trial: 23686379
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care + daily CP mouth rinses (n=27)
Trial: 22139337
Drug: Betacarotene (BC)
RxNorm normalized name: betacarotene
DrugBank: Beta carotene (DB06755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betacarotene (BC) group supplemented daily with 50 mg of BC (n=9; LW: 17.3±1.0 kg; BCS: 3.34±0.12)
Trial: 19109408
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg in pellet form
Trial: 17003088
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin (sc insulin)
Trial: 11261319
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g once daily plus tobramycin 5 mg/kg
Trial: 11261319
Drug: Cefotaxime 2
RxNorm normalized name: cefotaxime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 2 g three times daily plus tobramycin 5 mg/kg
Trial: 9249099
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg intravenous ibuprofen
Trial: 8034237
Drug: 5,000 IU
RxNorm normalized name: bleopmycin 15,000 IU Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,000 IU unfractionated (UF) heparin
Trial: 8034237
Drug: 1,500 activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,500 activated partial thromboplastin time units low molecular mass (LMM) heparin
Trial: 2894979
Drug: Felodipine (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (5, 10, 20 mg bid)
Trial: 2894979
Drug: Prazosin (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (1, 2, 4 mg bid)
Trial: 17371337
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg/day)
Trial: 26512149
Drug: Garcin tablets
RxNorm normalized name: GARCINIA MANGOSTANA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garcin tablets 1,500 mg daily for 7 days
Trial: 26512149
Drug: Fluconazole tablets
RxNorm normalized name: Fluconazole Tablets
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole tablets 150 mg daily for 7 days
Trial: 23221480
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with tamsulosin (0.4 mg) and fesoterodine extended-release
Trial: 23221480
Drug: Single administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single administration of tamsulosin (0.4 mg)
Trial: 21975559
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (5 mg IV infusion)
Trial: 16868359
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg dried garlic powder
Trial: 10487669
Drug: Hydrocortisone administration
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone administration at 1700 h
Trial: 10487669
Drug: Hydrocortisone administration
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone administration at 0500 h
Trial: 3493794
Drug: Propofol 3
RxNorm normalized name: fospropofol 35 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 3 mg kg‐1
Trial: 6811237
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g human immunoglobulin i.v. over four months
Trial: 21310051
Drug: ondansetron syrup
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ondansetron syrup (0.15 mg/Kg of body weight)
Trial: 21310051
Drug: domperidone syrup
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: domperidone syrup (0.5 mg/Kg of body weight)
Trial: 19797255
Drug: Spontaneous or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spontaneous or inducible VT as indication for ICD therapy
Trial: 9462489
Drug: 11 mg/d
RxNorm normalized name: ProStep 11 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11 mg/d transdermal nicotine
Trial: 9462489
Drug: 22 mg/d
RxNorm normalized name: ProStep 22 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 mg/d transdermal nicotine
Trial: 9462489
Drug: 44 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44 mg/d transdermal nicotine
Trial: 1970466
Drug: Zidovudine, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine, 200 mg orally every 4 hours
Trial: 6861859
Drug: Standard formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formulation of furosemide
Trial: 27903345
Drug: 70 kV
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70 kV CT angiography with 0.8 ml/kg contrast agent
Trial: 27903345
Drug: 120 kV
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120 kV CT angiography with 100 ml contrast agent
Trial: 25445073
Drug: Exposure-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based therapy with safety behavior assessment
Trial: 22178539
Drug: Neridronate 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neridronate 12.5 mg